Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ultragenyx Pharmaceutical Inc.

< Previous 1 2 3 4 Next >
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Participate in Investor Conferences in December
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Participate in Investor Conferences in September
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers MREO RARE
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Tickers RARE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.